Carlsmed (CARL) Cash & Equivalents (2024 - 2026)

Carlsmed's Cash & Equivalents history runs 3 years deep, the most recent figure standing at $73.0 million for Q1 2026.

• Quarterly Cash & Equivalents rose 68.12% year-over-year to $73.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.0 million (up 68.12% YoY) and the FY2025 annual result came in at $85.8 million, up 113.81% from the prior year.
• Cash & Equivalents was $73.0 million for Q1 2026 at Carlsmed, down from $85.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $115.4 million in Q3 2025 and bottomed at $33.5 million in Q2 2025.
• A 3-year average of $59.2 million and a median of $43.9 million in 2024 frame the typical range for Cash & Equivalents.
• Peak annual rise in Cash & Equivalents reached 159.68% in 2025, while the deepest fall reached 12.26% in 2025.
• Carlsmed's Cash & Equivalents stood at $40.1 million in 2024, then soared by 113.81% to $85.8 million in 2025, then slipped by 14.89% to $73.0 million in 2026.
• Business Quant data shows CARL's Cash & Equivalents at $73.0 million in Q1 2026, $85.8 million in Q4 2025, and $115.4 million in Q3 2025.